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Abstract
Aims: Elevated sex hormone-binding globulin (SHBG) concentrations have been 
described in patients with type 1 diabetes mellitus (t1DM), probably due to low 
portal insulin concentrations. We aimed to investigate whether the route of insulin 
administration, continuous intraperitoneal insulin infusion (CIPII), or subcutaneous (SC), 
influences SHBG concentrations among t1DM patients.
Methods: Post hoc analysis of SHBG in samples derived from a randomized, open-labeled 
crossover trial was carried out in 20 t1DM patients: 50% males, mean age 43 (±13) years, 
diabetes duration 23 (±11) years, and hemoglobin A1c (HbA1c) 8.7 (±1.1) (72 (±12) mmol/
mol). As secondary outcomes, testosterone, 17-β-estradiol, luteinizing hormone (LH), and 
follicle-stimulating hormone (FSH) were analyzed.
Results: Estimated mean change in SHBG was −10.3 nmol/L (95% CI: −17.4, −3.2) during 
CIPII and 3.7 nmol/L (95% CI: −12.0, 4.6) during SC insulin treatment. taking the effect of 
treatment order into account, the difference in SHBG between therapies was −6.6 nmol/L 
(95% CI: −17.5, 4.3); −12.7 nmol/L (95% CI: −25.1, −0.4) for males and −1.7 nmol/L (95% CI: 
−24.6, 21.1) for females, respectively. Among males, SHBG and testosterone concentrations 
changed significantly during CIPII; −15.8 nmol/L (95% CI: −24.2, −7.5) and −8.3 nmol/L 
(95% CI: −14.4, −2.2), respectively. the difference between CIPII and SC insulin treatment 
was also significant for change in FSH 1.2 U/L (95% CI: 0.1, 2.2) among males.
Conclusions: SHBG concentrations decreased significantly during CIPII treatment. 
Moreover, the difference in change between CIPII and SC insulin therapy was significant 
for SHBG and FSH among males. these findings support the hypothesis that portal 
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Among type 1 diabetes mellitus (T1DM) patients, 
subcutaneous (SC) insulin administration is associated 
with low portal insulin concentrations and a 
consequent hepatic underinsulinization (1). Hepatic 
underinsulinization has been suggested to influence 
several extra-glycemic, metabolic, and endocrinological 
parameters, such as the sex hormone-binding globulin 
(SHBG). SHBG is a glycoprotein produced in the liver, 
which regulates the bioavailability of sex steroids for 
target tissues and cells in the plasma (2). SHBG tends to 
be elevated among adult T1DM patients when compared 
with control subjects, possibly leading to changes in the 
bioavailability of gonadotropins and sex steroids (1, 3, 4, 
5, 6, 7, 8, 9, 10, 11, 12, 13).
Previous research has demonstrated that SHBG con-
centrations are inversely associated with (fasting) insulin 
concentrations in vivo (1, 6, 9, 14, 15, 16). Furthermore, 
in vitro, insulin has an inhibitory effect on the basal and 
stimulated SHBG production by HepG2 cells of the liver 
(17). Yki-Järvinen and coworkers previously suggested that 
portal insulin concentrations, and not insulin sensitivity, 
determines SHBG concentrations in T1DM patients (1). 
With continuous intraperitoneal insulin infusion (CIPII), 
insulin is infused in the intraperitoneal space and absorbed 
to a large extent in the portal vein catchment area (18, 19, 
20). Hence, CIPII will result in higher portal insulin con-
centrations and lower peripheral plasma insulin concentra-
tions, creating a more physiological situation as compared 
with SC insulin administration (19, 20, 21, 22).
We hypothesized that treatment with CIPII would 
result in lower SHBG concentrations as compared 
with SC insulin treatment. Therefore, the aim of this 
study was to analyze the effects of the route of insulin 
administration, CIPII versus SC, on SHBG concentrations 
in T1DM patients. As alterations in SHBG concentrations 
may result in changes of gonadotropins and sex 
steroids, concentrations of luteinizing hormone (LH), 
follicle-stimulating hormone (FSH), testosterone, and 
17-β-estradiol were also assessed.
Subjects, materials and methods
Study design
This study is a post hoc analysis of a randomized, open-label 
crossover trial that was carried out in a single center (Isala, 
Zwolle, The Netherlands) (23). The aim of this crossover 
trial was to investigate the influence of CIPII versus SC 
insulin treatment on glycemic control and hypoglycemic 
events among T1DM patients. Full design and outcomes 
have been published previously (23).
Study procedures
The crossover trial was divided into four phases: the 
qualification phase, the first treatment phase, the crossover 
phase, and the second treatment phase. The qualification 
phase had a duration of 3 months. During this period, 
it was attempted to achieve optimization of the patients’ 
glycemic control on the current SC insulin treatment, 
for example, multiple daily injections (MDI) or (mostly) 
continuous subcutaneous insulin infusion (CSII). After 
the qualification phase, patients were randomized into 
the first treatment phase to continue with SC insulin 
administration or start with CIPII using an implantable 
insulin pump. Both treatment phases were of 6 months 
duration with a crossover phase of 4 weeks in between, in 
which patients received SC insulin, to minimize possible 
carry-over effects of CIPII.
At the start of the CIPII phase, the insulin pump 
(MIP 2007C; Medtronic/Minimed, Northridge, CA, USA) 
was implanted under general anesthesia in all subjects. 
Insulin (U400 semi-synthetic human insulin of porcine 
origin; Sanofi-Aventis, Frankfurt, Germany) was admin-
istered through the implanted pump. For patients who 
received SC insulin treatment in the second treatment 
phase, the CIPII pump remained in situ, but was filled 
with an inert fluid at the end of the first treatment phase. 
During the SC treatment phase, patients used their own 
mode of SC insulin treatment consisting of rapid-acting 
insulin analogs (for CSII) combined with a long-acting 
analog (for MDI).
Study population
Subjects with T1DM with fasting C-peptide concentrations 
<0.2 nmol/L and intermediate or poor glycemic control, 
defined as HbA1c ≥7.5% (58 mmol/mol) and/or ≥5 
incidents of confirmed hypoglycemia (<4.0 mmol/L) per 
week, were eligible for participation in the study. A total 
of 24 patients were included and randomly allocated into 
one of the two treatment sequences. One patient who was 
allocated to start with CIPII treatment withdrew informed 
consent shortly after implantation of the insulin pump. As 
a result, 23 patients completed the follow-up period (23).
For the current analysis, patients with a known his-
tory of polycystic ovary syndrome (PCOS), hirsutism, 
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elevated androgen levels, alopecia, acromegaly, hypo-
thyroidism, hyperthyroidism, liver cirrhosis, and use of 
oral contraceptive or anti-epileptic drugs were excluded.
Measurements
The following data were recorded at baseline: smoking, 
alcohol habits, height, weight, any comorbidity, year 
of diagnosis of diabetes, C-peptide levels, medication, 
and presence of microvascular and macrovascular 
complications.
HbA1c was measured at baseline, at the end of the 
qualification phase, and at the start, halfway, and at the 
end of both treatment phases using a Primus Ultra 2 with 
high-performance liquid chromatography (reference 
value 4.0 – 6.0% (20 – 42 mmol/mol)). Measurements of 
SHBG, testosterone, 17-β-estradiol, LH, and FSH were 
performed in 1.5 cc serum samples that were collected 
at baseline and at the start, halfway, and at the end 
of both treatment phases. All samples were collected 
at non-fasting moments and stored at −80°C until 
analysis. Measurements were performed using a Cobas 
e601 immunoassay analyzer (Roche Diagnostics). The 
inter-assay coefficients of variation (CV) were <6% for 
SHBG, <8% for testosterone if >1.6 nmol/L or <20% if 
<1.6 nmol/L, <10% for 17-β-estradiol, <6% for LH, and 
<6% for FSH. Measurements performed at the start, 
halfway, and at the end of both treatment phases were 
used for analysis.
Primary and secondary outcomes
The primary outcome was the difference in SHBG 
concentrations between the CIPII and SC treatment 
phase. Secondary outcomes included the course of SHBG 
concentrations during both treatment phases. Because 
of known gender differences and because collection of 
samples took place irrespective of phase of the menstrual 
cycle, the results of SHBG and testosterone were presented 
for males and females separately and the results of 
17-β-estradiol, LH, and FSH were only presented for males.
Statistical analysis
To calculate the estimated mean difference, with a 95% 
confidence interval (CI), between the two therapies, the 
linear mixed models analysist that takes treatment order 
into account was used according to the Hills–Armitage 
principle. This accounts for any period effect. To test 
whether variables had a normal distribution, Q-Q plots 
were used. SHBG, testosterone, 17-β-estradiol, LH, and FSH 
had a skewed distribution and were presented as median 
and interquartile ranges. Both observed and estimated 
outcomes were reported. Comparisons between outcomes 
during both treatment modalities were made using the 
Wilcoxon signed-rank test for non-parametric data. Data 
were presented as total number (% of total group), mean 
(s.d.), or median with interquartile range [IQR]. A two-
sided P-value of <0.05 was considered to be significant. All 
analyses were performed using SPSS version 22 software.
The study was carried out in accordance with the 
Declaration of Helsinki and the protocol was approved by 
the Medical Ethics Committee of Isala, Zwolle. Informed 
consent from all patients was obtained.
Results
Study population
A total number of 23 patients completed the original 
crossover trial. For the current analysis, three patients 
were excluded due to the use of oral contraceptive drugs 
(n = 1) and hypothyroidism (n = 2). At baseline, there were 
no significant differences between patients who started 
CIPII or SC insulin treatment in the first phase regarding 
clinical and biochemical characteristics (Table 1).
Primary outcome: SHBG concentrations
The observed concentrations of SHBG at the start, 
halfway, and end of the CIPII and SC treatment phases 
are presented in Table  2. The estimated mean change 
in SHBG concentrations during the CIPII phase was 
−10.3 nmol/L (95% CI: −17.4, −3.2) and −3.7 nmol/L 
(95% CI: −12.0, 4.6) during the SC phase. When taking 
the effect of treatment order into account, the estimated 
mean difference between the CIPII and SC treatment 
phases was −6.6 nmol/L (95% CI: −17.5, 4.3). No carry-
over effect was observed (P = 0.226).
Secondary outcome: SHBG, testosterone, 
17-β-estradiol, LH, and FSH concentrations
Among males, SHBG decreased significantly −15.8 nmol/L 
(95% CI: −24.2, −7.5) during CIPII treatment, while 
there was no significant change during SC treatment 
(Table  2). When taking the effect of treatment order 
into account, the estimated mean change between the 
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CIPII treatment phase and the SC treatment phase was 
−12.7 nmol/L (95% CI: −25.1, −0.4). Among males, only 
the testosterone concentrations decreased significantly 
during CIPII treatment with −8.3 nmol/L (95% CI: −14.4, 
−2.2) and FSH concentrations increased significantly with 
CIPII treatment when compared with SC insulin therapy 
with 1.1 U/L (95% CI: 0.1, 2.2) (Table 3). Among females, 
there were no changes in SHBG and testosterone within 
and between both treatment modalities.
Discussion
Treatment with CIPII resulted in a significant decrease 
of SHBG concentrations, while concentrations 
remained stable during treatment with SC insulin. The 
difference between both treatment modalities in SHBG 
concentrations was significant among men. These findings 
provide support for the hypothesis that enhancing portal 
insulin levels, through treatment with CIPII, influences 
circulating SHBG concentrations.
Although the exact mechanism remains unknown, 
an inhibitory effect of insulin on the synthesis of SHBG 
seems a valid explanation, as direct inhibition of SHBG 
synthesis by insulin has been observed in HepG2 cells in 
the liver, both in vitro and in vivo (1, 6, 9, 14, 15, 16). 
Since there is (almost) no endogenous insulin production 
in T1DM patients, an increase of portal insulin concen-
tration with CIPII and the subsequent increased hepatic 
insulinization may cause a more pronounced suppression 
of SHBG production. Apart from portal insulin concen-
trations, other factors such as glycemic control, insulin 
dose, insulin resistance, and the presence of microvascu-
lar complications have been suggested to influence SHBG 
concentrations (1, 4, 14, 17) among T1DM patiets.
In a previous study, Lassmann-Vague and coworkers 
measured SHBG concentrations before and after 
initiation of CIPII among 11 T1DM patients (5 males and 
6 females) and found a decrease of SHBG concentrations 
after 3 months of CIPII therapy as compared with prior 
SC insulin treatment: 41 ± 4 to 33 ± 2 nM/L for males and 
84 ± 6 to 63 ± 8 nM/L for females (9). The current study 
confirms these results and adds by describing an increase 
in FSH and a decrease in testosterone concentrations 
during CIPII treatment among males. These changes may 
be accounted to as a refractory response to altered SHBG 
levels. Although speculative, a direct effect of insulin on 
testosterone by selectively inhibiting adrenal androgen 
production by suppressing 17,20-lyase activity in females 
may be an alternative explanation (24).
The nonsignificant change of SHBG concentrations 
in the total group between both routes of insulin adminis-
tration may be explained by the small sample size (n = 20) 
and/or the duration of the study. Nevertheless, among 
males, the difference in change between both routes of 
insulin administration was significant for SHBG and FSH. 
Although hypothetically, these gender differences may be 
due to differences in SHBG function, in particular a lower 
testosterone binding degree of SHBG in female, different 
(testosterone related) gonadotropin feedback on SHBG 
synthesis, and cycle variation (25, 26, 27, 28).
Alterations found in SHBG and testosterone con-
centrations might be associated with disorders with an 
increased incidence among T1DM patients such as repro-
ductive disorders, PCOS, increased risk of osteoporotic 
fractures in females, and a tendency to hypogonadism in 
males (29, 30, 31, 32, 33, 34, 35, 36, 37). Moreover, low 
testosterone concentrations were recently associated with 
the development of microvascular and macrovascular 
complications (38). However, the clinical consequences 
of the current study are unclear at present.
When interpreting the results of this study, several 
limitations should be taken into account. First and fore-
most, the original study was not designed to detect differ-
ences in SHBG concentrations. Consequently, the sample 
Table 1 Baseline characteristics of all patients.





N 20 10 10
Age (years) 43.1 (12.7) 42.5 (13.0) 43.6 (13.1)
Gender (male) 10 (50) 5 (50) 5 (50)
Weight (kg) 82.5 (16.4) 81.3 (18.7) 83.7 (14.5)
BMI (kg/m2) 26.6 (5.1) 26.2 (5.8) 26.9 (4.6)
Diabetes duration 
(years)
23.4 (11.0) 20.5 (10.6) 26.4 (11.2)
HbA1c (%) 8.7 (1.1) 8.7 (1.1) 8.7 (1.2)
HbA1c (mmol/mol) 71.5 (12.3) 71.4 (11.7) 71.7 (13.5)
Macrovascular 
complications
2 (10) 1 (10) 1 (10)
Microvascular 
complications
9 (45) 5 (50) 4 (40)
  Neuropathy 6 (30) 3 (30) 3 (30)
  Nephropathy 1 (5) 0 (0.0) 1 (10)
  Retinopathy 6 (30) 2 (20) 4 (40)

















Data are presented as: a number (% of total group), mean (s.d.), or 
median [IQR]. Numbers may not add up due to rounding. Macrovascular 
complications: PCI (n = 1) and angina pectoris (n = 1).
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size was small, blood samples were taken at random, non-
standardized moments and at non-fasting moments and 
the effect of other factors suggested to influence SHBG and 
sex hormone synthesis, that is, microvascular complica-
tions, insulin-like growth factors, menstrual cycle, mono-
saccharides, and oxative stress levels in the liver remain 
unknown (39, 40, 41). Due to these limitations, we also 
did not measure free testosterone as these measurements 
are challenging (42). Adding them could have led to (addi-
tional) limitations to our data and would increase the 
chance to make a type I error. Because of low testosterone 
concentrations among females, the coefficient of the assays 
(estimated to be >20% in the range of 0.15 – 0.50 nmol/L) 
may also have influenced these results. The use of porcine 
insulin in the CIPII group, used for CIPII until 2010 due to 
delayed progress in the development of new insulin, may 
also have influenced the results. Finally, there was a lack of 
a non-T1DM reference population.
Nevertheless, this study is the first to describe the 
effects of different routes of insulin administration 
on SHBG, sexual steroids, and gonadotropins among 
T1DM patients. Furthermore, this study provides proof-
of-principle and supports the hypothesis that portal 
insulin administration has an effect on circulating SHBG 
concentrations and on sexual steroids, in particular in 
male T1DM patients. The effects of various routes of 
insulin administration on SHBG, steroids, and associated 
pathology merit further study.
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